Context Therapeutics (NASDAQ:CNTX) told investors that a poster regarding its preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody, will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center.
The presentation will take place from 9am to 7pm PT on November 3 in Exhibit Halls A and B1 at the center. For more information and to view the abstract, visit the SITC 38th Annual Meeting website.